News

Tensions between broad access to new medical technologies and efforts to contain health care costs are perennial. In recent years, this has become evident in the uncomfortable discontinuities that can occur between health technology assessment (HTA) and regulatory approval of medicines. In autumn 2009, OHE and the Institute for Regulatory Science at CMR International collaborated on a two-day workshop on the issues raised.

On 29 June, OHE will collaborate with the Pope Woodhead consultancy to present a workshop on implementing risk sharing and patient access schemes within a market access strategy. Delivered in a highly interactive format, the day will include ample opportunity for lively discussion, group break-outs, role playing scenarios and the sharing of experiences.

In an article in Health Economics, Prof Devlin and her co-authors demonstrate the promise of using Lead Time TTO to value health 'state worse than death'. They demonstrate the potential advantages of the approach and identify important next steps in developing the methodology.

Pages